Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05461014 · ClinicalTrials.gov registry record · NA
RxWell in Pediatric IBD for Disease Management and Transition Readiness
A NA study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT05461014 is a NA study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 7 participants.
The verdict
NCT05461014, a NA study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
Evaluate the feasibility and acceptability of adapted coached RxWell for patients ages 16-25. Adapt and beta test the modified RxWell product to include chronic disease management and transition readiness. Evaluate RxWell usage and its impact to the TRAQ questionnaire over time.
Interventions
- BEHAVIORAL dCBI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-07-30 |
| Est. Completion | 2023-03-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05461014
The ClinicalTrials.gov registry entry for NCT05461014 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dCBI is the first listed.
NCT05461014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05461014 about?
NCT05461014 is a clinical study titled "RxWell in Pediatric IBD for Disease Management and Transition Readiness". Evaluate the feasibility and acceptability of adapted coached RxWell for patients ages 16-25. Adapt and beta test the modified RxWell product to include chronic disease management and transition readiness. Evaluate RxWell usage and its impact to the TRAQ questionnaire over time.
What is the current status of trial NCT05461014?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2022-07-30. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT05461014?
The interventions under investigation include: dCBI (BEHAVIORAL).
Who is sponsoring clinical trial NCT05461014?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.